Setmelanotide for Obesity

"As of now, this medical research is accepting participants from twelve different centres. Some cities that are included in the list are Houston, Suwanee and Dearborn along with nine other locales. To make sure your commute is as short as possible, consider joining a trial at the closest location to you."

"POMC or PCSK1 variant are both suitable treatments for chronic weight management therapy, obesity, and POMC deficiency obesity."

"Information available on clinicaltrials.gov indicates that this medical trial is currently accepting applications; the initial posting was made on December 10th 2021, with the last update occuring on November 21st 2022."

"In 2018, the Marshfield Clinic Research Institute first evaluated POMC and PCSK1 variants. Since then, 18339 trials have been completed in total - 4 of which are ongoing and conducted primarily from Houston, GA."

"To adequately conduct the trial, Rhythm Pharmaceuticals, Inc. requires 400 participants who satisfy its inclusion criteria. Two medical centres have been identified to manage the study: Texas Children's Hospital in Houston and InQuest Medical Research in Suwanee, Michigan."

"This trial is recruiting 400 individuals between the ages of 6 and 65 who are currently living with obesity. Participants must also present a Heterozygous genetic variant in either the POMC or PCSK1 gene, Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, 16p11.2 chromosomal deletion encompassing SH2B1 gene; BMI ≥30 kg/m² for those aged 18+ and ≥ 95th percentile for those under 17 years; have tried to treat their condition through diet and exercise before enrolling; agree to use highly effective contraception during the study period as"

"The POMC or PCSK1 variant has been evaluated with a score of 3, as the Phase 3 trial it is part of provides ample evidence for both its efficacy and safety."

"This clinical trial is seeking participants aged between 6 and 65. For those outside of this range, there are 206 trials for individuals below 18 years old and 599 studies available to patients above the age of 65."

"Rhythm Pharmaceuticals, Inc. is behind the initial trial for POMC or PCSK1 variant from 2018, which has since progressed through both Phase 2 and 3 drug approval stages with 150 participants involved. Since then, 38 cities across 10 countries have seen 4 active studies involving a total of 18339 trials conducted in the past four years."